we develop monoclonal antibodies against cancer metastasis: the industry's 1st antibody to extracellular HSP 90, a validated oncology target
Zestagen is a virtual, single-asset biotech. We develop monoclonal antibodies against Extracellular Heat Shock Protein-90 (ehsp90), a protein implicated in cancer metastasis. ehsp90 is detectable at the surface of cancer cells but not of normal cells. Our mAbs bind ehsp90 at the surface of cancer cells (but not normal cells) leading to significant inhibition of metastasis -in the absence of discernible toxicity- in preclinical animal models.